A Potent Combination of the Novel PI3K Inhibitor, GDC-0941, with Imatinib in Gastrointestinal Stromal Tumor Xenografts: Long-Lasting Responses after Treatment WithdrawalGiuseppe Floris, Patrick Schöffski, Agnieszka Woźniak et al.|Clinical Cancer Research|2012Cited by 69
The HSP90 Inhibitor, AT13387, Is Effective against Imatinib-Sensitive and -Resistant Gastrointestinal Stromal Tumor ModelsTomoko Smyth, Nicola G. Wallis, Thomas Van Looy et al.|Molecular Cancer Therapeutics|2012Cited by 59
Phosphoinositide 3-Kinase Inhibitors Combined with Imatinib in Patient-Derived Xenograft Models of Gastrointestinal Stromal Tumors: Rationale and EfficacyThomas Van Looy, Patrick Schöffski, Agnieszka Woźniak et al.|Clinical Cancer Research|2014Cited by 50
Characterization and assessment of the sensitivity and resistance of a newly established human gastrointestinal stromal tumour xenograft model to treatment with tyrosine kinase inhibitorsThomas Van Looy, Patrick Schöffski|Clinical Sarcoma Research|2014Cited by 26
Table S2 from Phosphoinositide 3-Kinase Inhibitors Combined with Imatinib in Patient-Derived Xenograft Models of Gastrointestinal Stromal Tumors: Rationale and EfficacyThomas Van Looy, Patrick Schöffski, Agnieszka Woźniak et al.|Unknown|2023Cited by 0